- Home
- BIVI vs LYRA Comparison
BIVI vs LYRA Comparison
Compare BIVI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- LYRA
- Stock Information
- Founded
- BIVI 2013
- LYRA 2005
- Country
- BIVI United States
- LYRA United States
- Employees
- BIVI N/A
- LYRA N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- BIVI Health Care
- LYRA Health Care
- Exchange
- BIVI Nasdaq
- LYRA Nasdaq
- Market Cap
- BIVI 11.9M
- LYRA 11.3M
- IPO Year
- BIVI N/A
- LYRA 2020
- Fundamental
- Price
- BIVI $1.87
- LYRA $6.35
- Analyst Decision
- BIVI
- LYRA Hold
- Analyst Count
- BIVI 0
- LYRA 1
- Target Price
- BIVI N/A
- LYRA $16.00
- AVG Volume (30 Days)
- BIVI 316.9K
- LYRA 14.7K
- Earning Date
- BIVI 11-12-2025
- LYRA 11-11-2025
- Dividend Yield
- BIVI N/A
- LYRA N/A
- EPS Growth
- BIVI N/A
- LYRA N/A
- EPS
- BIVI N/A
- LYRA N/A
- Revenue
- BIVI N/A
- LYRA $770,000.00
- Revenue This Year
- BIVI N/A
- LYRA N/A
- Revenue Next Year
- BIVI N/A
- LYRA $123.46
- P/E Ratio
- BIVI N/A
- LYRA N/A
- Revenue Growth
- BIVI N/A
- LYRA N/A
- 52 Week Low
- BIVI $1.42
- LYRA $3.81
- 52 Week High
- BIVI $75.00
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- BIVI 33.55
- LYRA 36.31
- Support Level
- BIVI $1.54
- LYRA $6.03
- Resistance Level
- BIVI $1.68
- LYRA $6.90
- Average True Range (ATR)
- BIVI 0.14
- LYRA 0.40
- MACD
- BIVI 0.26
- LYRA -0.03
- Stochastic Oscillator
- BIVI 73.77
- LYRA 21.78
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.